Dengqiu Xu, Lei Zhao, Jingwei Jiang, Sijia Li, Zeren Sun, Xiaofei Huang, Chunjie Li, Tao Wang, Lixin Sun, Xihua Li, Zhenzhou Jiang, Luyong Zhang
BACKGROUND: Duchenne muscular dystrophy (DMD) is a progressive muscle disease caused by the loss of dystrophin, which results in inflammation, fibrosis, and the inhibition of myoblast differentiation in skeletal muscle. Catalpol, an iridoid glycoside, improves skeletal muscle function by enhancing myogenesis; it has potential to treat DMD. We demonstrate the positive effects of catalpol in dystrophic skeletal muscle. METHODS: mdx (loss of dystrophin) mice (n = 18 per group) were treated with catalpol (200 mg/kg) for six consecutive weeks...
August 31, 2020: Journal of Cachexia, Sarcopenia and Muscle